P.040 Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

نویسندگان

چکیده

Background: The 26-week double-blind, randomized, placebo-controlled period (RCP) of the CHAMPION MG study (NCT03920293) demonstrated ravulizumab’s efficacy and tolerability in anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). Methods: In ongoing open-label extension (OLE), patients receive intravenous ravulizumab (blind loading dose placebo-treated or bridging ravulizumab-treated patients, then 3000–3600 mg according to body weight every 8 weeks) for ≤4 years. Data from RCP baseline up Week 60 were analyzed. Results: Ravulizumab’s long-term (n=161) safety (n=169) assessed. Patients who switched placebo OLE (n=83) showed rapid improvement (least squares mean, 95%CI) Myasthenia Gravis-Activity Daily Living (MG-ADL) Quantitative Gravis (QMG) total scores, which maintained through 34 weeks (MG-ADL: −1.7, −2.7 −0.8; QMG: −3.1, −4.2 −1.9). Improvements achieved by (n=78) sustained −4.0, −4.8 −3.1; −4.1, −5.4 −2.9). Ravulizumab was well tolerated; no meningococcal infections reported. Four deaths unrelated treatment occurred. Conclusions: improvements symptoms tolerated adults with AChR Ab+ gMG.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Deficiencies in anti-acetylcholine receptor antibody measurement in myasthenia gravis.

In a retrospective case note study of 86 patients with myasthenia gravis, 60 had an anti-acetylcholine receptor antibody assay performed by the regional immunology laboratory. Antibody was detected in 38% which compares with 66-93% in other series. Whilst the use of staphylococcal protein A to precipitate the antibody-receptor complex, rather than anti-human immunoglobulin, may be partly respon...

متن کامل

Acetylcholine receptor antibody positive generalized myasthenia gravis in association with primary biliary cirrhosis.

Primary Biliary Cirrhosis and Myasthenia Gravis are both autoimmune conditions, however, there are only rare case reports of their association. This is a case report of acetylcholine receptor antibody positive generalized myasthenia gravis in a female patient with antimitochondrial antibody positive, liver biopsy-confirmed primary biliary cirrhosis.

متن کامل

Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody.

Myasthenia gravis (MG) is a human autoimmune disease mediated by anti-acetylcholine receptor (AChR) antibodies. The thymus is probably the site where the autoimmune response is triggered and maintained. Recent reports have linked various autoimmune disease with defective Fas expression. We thus analyzed Fas expression in thymocytes and peripheral blood lymphocytes (PBL) from MG patients. The pr...

متن کامل

Facial and bulbar muscle atrophy in acetylcholine receptor antibody-positive myasthenia gravis.

A 62-year-old man presented with seven years of progressive dysphagia, dysphonia and difficulty in closing both eyes. His examination showed weakness and atrophy of facial and bulbar muscles without ocular involvement (Figure A, B and C). Single-fiber electromyography revealed increased jitter (Figure D). To evaluate for concurrent myopathy, a muscle biopsy was performed and showed angulated at...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Canadian Journal of Neurological Sciences

سال: 2023

ISSN: ['2057-0155', '0317-1671']

DOI: https://doi.org/10.1017/cjn.2023.144